Table 1.
Examine the prognosis of MCMs in glioma patients analysis by cox regression.
| Characteristics | Total(N) | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|
| Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | ||
| WHO grade | 466 | ||||
| G2 | 223 | ||||
| G3 | 243 | 3.059 (2.046-4.573) | <0.001 | 2.986 (1.578-5.652) | <0.001 |
| 1p/19q codeletion | 527 | ||||
| codel | 170 | ||||
| non-codel | 357 | 2.493 (1.590-3.910) | <0.001 | 3.892 (1.455-10.405) | 0.007 |
| Primary therapy outcome | 457 | ||||
| PD | 110 | ||||
| SD | 146 | 0.439 (0.292-0.661) | <0.001 | 0.361 (0.187-0.697) | 0.002 |
| PR | 64 | 0.175 (0.076-0.402) | <0.001 | 0.261 (0.079-0.868) | 0.028 |
| CR | 137 | 0.122 (0.056-0.266) | <0.001 | 0.210 (0.088-0.501) | <0.001 |
| IDH status | 524 | ||||
| WT | 97 | ||||
| Mut | 427 | 0.186 (0.130-0.265) | <0.001 | 0.574 (0.258-1.276) | 0.173 |
| Histological type | 393 | ||||
| Astrocytoma | 195 | ||||
| Oligodendroglioma | 198 | 0.577 (0.392-0.849) | 0.005 | 0.705 (0.362-1.371) | 0.303 |
| Gender | 527 | ||||
| Female | 238 | ||||
| Male | 289 | 1.124 (0.800-1.580) | 0.499 | ||
| Race | 508 | ||||
| Black or African American | 22 | ||||
| White | 486 | 0.686 (0.319-1.471) | 0.333 | ||
| Age | 527 | ||||
| <=40 | 264 | ||||
| >40 | 263 | 2.889 (2.009-4.155) | <0.001 | 3.734 (2.111-6.606) | <0.001 |
| MCM2 | 527 | 1.608 (1.396-1.852) | <0.001 | 0.546 (0.302-0.989) | 0.046 |
| MCM3 | 527 | 1.929 (1.585-2.347) | <0.001 | 0.640 (0.243-1.683) | 0.366 |
| MCM4 | 527 | 1.722 (1.447-2.051) | <0.001 | 3.494 (1.580-7.722) | 0.002 |
| MCM5 | 527 | 1.907 (1.543-2.357) | <0.001 | 1.717 (0.849-3.473) | 0.132 |
| MCM6 | 527 | 1.848 (1.517-2.251) | <0.001 | 2.792 (1.231-6.330) | 0.014 |
| MCM7 | 527 | 1.350 (1.098-1.660) | 0.004 | 0.503 (0.265-0.953) | 0.035 |
| MCM8 | 527 | 2.029 (1.702-2.419) | <0.001 | 0.857 (0.398-1.847) | 0.694 |
| MCM9 | 527 | 1.704 (1.108-2.621) | 0.015 | 0.471 (0.193-1.148) | 0.098 |
| MCM10 | 527 | 1.330 (1.180-1.500) | <0.001 | 0.772 (0.478-1.249) | 0.292 |
WHO, World Health Organization’s; G2, Grade II; G3, Grade III; PD, progressive disease; SD, stable disease; PR, partial response; CR, complete response; WT, Wild Type; Mut: Mutant.